Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face

Fata, F. Ramón de; O’Reilly, Eileen M.; Ilson, David H.; Pfister, David G.; Leffel, David; Kelsen, David P.; Schwartz, Gary K.; Casper, Ephraim S.

doi:10.1002/(sici)1097-0142(19991115)86:10<2034::aid-cncr21>3.0.co;2-p

Cited by 354 publications

(135 citation statements)

References 13 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…The most frequent toxicities associated with this regimen were neutropenia and peripheral neuropathy. 25 We therefore tested an alternative approach to palliative treatment for patients with malignant vascular tumors based on recent research results regarding antiangiogenetic tumor therapy. One previous study reported the successful treatment of angiosarcomas with the antiangiogenetic agents TNP-470 and 2-methoxyestradiol in mice.…”

Section: Discussionmentioning

confidence: 99%

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

Vogt

Hafner

Bross

et al. 2003

Cancer

133

View full text Add to dashboard Cite

The processing–property relationship of a model cryogenically mechanically alloyed polymer–polymer system [polycarbonate (PC) and poly(aryl ether ether ketone) (PEEK)] was investigated. PC and PEEK powders were cryogenically mechanically alloyed for 10 h, and the resulting two‐phase powder particles were processed into testable coupons with a miniature ram‐injection molder. The bulk mechanical properties of the coupons made from the mechanically alloyed powders and nonmechanically alloyed powders were investigated as a function of mechanical alloying and injection‐molding parameters. The injection‐molded coupons were mechanically tested in the three‐point‐bending mode. The results demonstrated that no measurable improvement was achieved in the energy to break, strain at failure, or failure strength in the coupons made from the mechanically alloyed materials in comparison with those of the coupons made from the nonmechanically alloyed powders. © 2003 Wiley Periodicals, Inc. J Appl Polym Sci 88: 1196–1202, 2003

show abstract

Section: Discussionmentioning

confidence: 99%

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

Vogt

Hafner

Bross

et al. 2003

Cancer

133

View full text Add to dashboard Cite

show abstract

“…Recent data suggest that adjuvant chemotherapy with paclitaxel improves the condition of patients with soft-tissue sarcoma of the face or scalp [23,24]. In the case of skull angiosarcoma, however, the effectiveness of chemotherapy has not been substantiated.…”

Section: Discussionmentioning

confidence: 99%

Primary temporal bone angiosarcoma: a case report

et al. 2005

View full text Add to dashboard Cite

SummaryWe present a rare case of temporal bone angiosarcoma diagnosed in a 26-year-old female patient at 36 week of pregnancy. The patient was referred with a 2 months history of left otalgia and tinnitus with a tender swelling above the mastoid. Cranial imaging studies showed a 7 × 5 × 4 cm hypervascularized mass located in the left middle fossa with lysis of the temporal bone and extension to the subcutis. After the baby was delivered by caesarean section, the patient entered the oncology protocol. Selective embolization of the feeding vessels was followed by gross total surgical resection using a combined supra-and infra-tentorial approach. Pathological findings were those of a poorly differentiated, highly malignant sarcoma with a large epitheloid component and immunohistochemical evidence of endothelial differentiation (CD31, Factor VIII related antigen, CD34), consistent with an angiosarcoma with epitheloid features. No extra-cranial tumor was found after extensive staging. The patient received adjuvant radiotherapy followed by a course of chemotherapy consisting of 6 cycles of paclitaxel. At 15 months follow-up, she developed multiple distant metastasis to a left postauricular lymph node and to the lungs and ribs. The patient was given a second line chemotherapy using doxorubicine and ifosfamide. Despite an initial good response, she died with metastatic disease 26 months after diagnosis. We present a rare case of primary temporal bone angiosarcoma and report our experience with a multimode therapeutic approach combining surgery, radiotherapy and chemotherapy.

show abstract

“…Furthermore, synovial sarcoma is considered by experts to be sensitive to ifosfamide, in particular, although published data supporting this expert-based opinion are lacking. Paclitaxel, which has been shown to be inactive for the whole group of soft tissue sarcomas [21,22], yielded a promising, high response rate in patients with angiosarcoma of the scalp [37]. A similar situation holds true for the combination of gemcitabine and docetaxel.…”

Section: Histological Subtypesmentioning

confidence: 94%

Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard Care

2005

View full text Add to dashboard Cite

Learning ObjectivesAfter completing this course, the reader will be able to:1. Discuss the current status of the chemotherapeutic treatment of advanced soft tissue sarcomas in adult patients.2. Explain the pitfalls in trial design when reading published papers on performed clinical studies.3. Discuss the importance of identifying the several subtypes comprising the group of soft tissue sarcomas. AbstractThe group of soft tissue sarcomas in adult patients is a heterogeneous group with more than 40 different subtypes. While local treatment remains the mainstay for localized disease, systemic chemotherapy can importantly contribute in the treatment of advanced soft tissue sarcoma. For patients with metastatic disease, chemotherapy is a palliative treatment in the vast majority of the cases. In this setting, toxicity should not outweigh the potential benefits resulting from chemotherapy. In patients with locally advanced disease too extensive for local treatment, systemic chemotherapy can contribute to cure, provided that tumor shrinkage renders subsequent optimal local treatment possible. In these cases, chemotherapeutic regimens yielding the highest response rates achievable should be used. In the last decades, several randomized studies have aimed to determine whether combination regimens yield benefit over single-agent treatment in terms of response rate and overall survival. This review addresses the current available data on chemotherapy for adult patients with soft tissue sarcoma, excluding gastrointestinal stromal tumor, the Ewing-like sarcomas, and other small blue round cell tumors. In addition, it is increasingly recognized that future research in soft tissue sarcoma should focus on the identification of tumor factors that can serve as targets for treatment and that the diverse tumor subtypes should be analyzed separately for their sensitivity to systemic treatment. This review also focuses on these and other strategies that will hopefully lead to better outcomes in this disease entity in the near future. The Oncologist 2005;10:833-841 Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S.

show abstract

Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face

Cited by 354 publications

References 13 publications

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

Primary temporal bone angiosarcoma: a case report

Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard Care

Contact Info

Product

Resources

About